Literature DB >> 342617

Measurement of hemagglutination-inhibiting antibody to influenza virus in the 1976 influenza vaccine program: methods and test reproducibility.

G R Noble, H S Kaye, W B Yarbrough, B K Fiedler, C J Reed, M B Felker, A P Kendal, W R Dowdle.   

Abstract

Titers of hemagglutination-inhibiting (HAI) antibody were determined for all sera obtained from participants in the 1976 Influenza Vaccine Test Program. At least eight control sera were included in each test during the vaccine trial period for the purpose of monitoring HAI test reproducibility. Estimates of day-to-day reproducibility were defined as the percentages of duplicate aliquots of the same sera, tested on two separate days, having HAI antibody titers that did not differ by more than one twofold dilution. These reproducibility estimates ranged from 89% to 97% with influenza A/New Jersey/76 and A/Mayo Clinic/74 antigens. In contrast, within-day reproducibility estimates obtained from all sets of control sera ranged from 96% to 98%. Estimates of day-to-day test reproducibility obtained with selected sera taken after vaccination that were titrated on two differen days ranged from 90% to 98%. Geometric mean titers of these sera tested weeks or months apart differed on some occasions during the test period.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 342617     DOI: 10.1093/infdis/136.supplement_3.s429

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study.

Authors:  Corina Nailescu; Xiyan Xu; Hong Zhou; Henrietta Hall; Amy C Wilson; Jeffrey D Leiser; Deepa H Chand; Rudolph P Valentini; Diane Hebert; John D Mahan
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

2.  A practical approach to genetic screening for influenza virus variants.

Authors:  S Zou
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

3.  Evolution of the hemagglutinin gene of influenza B virus was driven by both positive and negative selection pressures.

Authors:  S Zou; I Prud'homme; J M Weber
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

4.  Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization.

Authors:  Jessica L Halliley; Shuya Kyu; James J Kobie; Edward E Walsh; Ann R Falsey; Troy D Randall; John Treanor; Changyong Feng; Ignacio Sanz; F Eun-Hyung Lee
Journal:  Vaccine       Date:  2010-03-16       Impact factor: 3.641

5.  Genetic characterization of the hemagglutinin gene of influenza B virus which predominated in the 1985/86 Canadian influenza season.

Authors:  S Zou; I Prud'homme; J M Weber
Journal:  Can J Infect Dis       Date:  1997-09

6.  Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.

Authors:  A P Kendal; F M Bozeman; F A Ennis
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

7.  CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses.

Authors:  Kristin Scheible; Gang Zhang; Jane Baer; Mitra Azadniv; Kris Lambert; Gloria Pryhuber; John J Treanor; David J Topham
Journal:  Vaccine       Date:  2011-01-04       Impact factor: 3.641

8.  Identification of new influenza B virus variants by multiplex reverse transcription-PCR and the heteroduplex mobility assay.

Authors:  S Zou; C Stansfield; J Bridge
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

9.  Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody.

Authors:  James J Kobie; John J Treanor; Christopher T Ritchlin
Journal:  Immunol Invest       Date:  2014       Impact factor: 3.657

10.  Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.

Authors:  James J Kobie; Bo Zheng; Peter Bryk; Michael Barnes; Christopher T Ritchlin; Darren A Tabechian; Allen P Anandarajah; R John Looney; Ralf G Thiele; Jennifer H Anolik; Andreea Coca; Chungwen Wei; Alexander F Rosenberg; Changyong Feng; John J Treanor; F Eun-Hyung Lee; Ignacio Sanz
Journal:  Arthritis Res Ther       Date:  2011-12-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.